FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio

Stock News12-18 18:32

FOSUN PHARMA (600196.SH) announced that on December 18, 2025, its subsidiary Fosun Pharma Industrial entered into a Collaboration and Option Agreement with Clavis Bio. Under the agreement, during the specified collaboration period, Fosun Pharma Industrial and Clavis Bio will jointly select targets (nominated by Clavis Bio) and advance preclinical development for compounds targeting these selected projects.

Clavis Bio retains an exclusive option to develop, manufacture, and commercialize these collaboration projects globally, excluding mainland China, Hong Kong, and Macau. Regardless of whether Clavis Bio exercises this option, the group retains exclusive rights to develop, manufacture, and commercialize the projects in mainland China, Hong Kong, and Macau.

If Clavis Bio exercises its option for any project, the group could receive up to $362.5 million in payments (including non-refundable option fees, development and registration milestone payments, and sales milestone payments). Additionally, the group will earn tiered royalties based on net sales of the licensed products in the designated regions.

Furthermore, the group will acquire a minority stake in a newly established project company by Clavis Bio’s controlling shareholder (Aditum Bio Fund 3) at zero cost. This collaboration aims to leverage both parties' R&D strengths, enrich the group’s high-value product pipeline, and accelerate global clinical development and commercialization through potential out-licensing, expanding the overseas footprint of its innovative products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115920738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115920738","market":"other","top_or_hot":-1,"title":"FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) announced that on December 18, 2025, its subsidiary Fosun Pharma Industrial entered into a Collaboration and Option Agreement with Clavis Bio. Under the agreement, during the specified collaboration period, Fosun Pharma Industrial and Clavis Bio will jointly select targets (nominated by Clavis Bio) and advance preclinical development for compounds targeting these selected projects.</p>\n<p>Clavis Bio retains an exclusive option to develop, manufacture, and commercialize these collaboration projects globally, excluding mainland China, Hong Kong, and Macau. Regardless of whether Clavis Bio exercises this option, the group retains exclusive rights to develop, manufacture, and commercialize the projects in mainland China, Hong Kong, and Macau.</p>\n<p>If Clavis Bio exercises its option for any project, the group could receive up to $362.5 million in payments (including non-refundable option fees, development and registration milestone payments, and sales milestone payments). Additionally, the group will earn tiered royalties based on net sales of the licensed products in the designated regions.</p>\n<p>Furthermore, the group will acquire a minority stake in a newly established project company by Clavis Bio’s controlling shareholder (Aditum Bio Fund 3) at zero cost. This collaboration aims to leverage both parties' R&D strengths, enrich the group’s high-value product pipeline, and accelerate global clinical development and commercialization through potential out-licensing, expanding the overseas footprint of its innovative products.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-18 18:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) announced that on December 18, 2025, its subsidiary Fosun Pharma Industrial entered into a Collaboration and Option Agreement with Clavis Bio. Under the agreement, during the specified collaboration period, Fosun Pharma Industrial and Clavis Bio will jointly select targets (nominated by Clavis Bio) and advance preclinical development for compounds targeting these selected projects.</p>\n<p>Clavis Bio retains an exclusive option to develop, manufacture, and commercialize these collaboration projects globally, excluding mainland China, Hong Kong, and Macau. Regardless of whether Clavis Bio exercises this option, the group retains exclusive rights to develop, manufacture, and commercialize the projects in mainland China, Hong Kong, and Macau.</p>\n<p>If Clavis Bio exercises its option for any project, the group could receive up to $362.5 million in payments (including non-refundable option fees, development and registration milestone payments, and sales milestone payments). Additionally, the group will earn tiered royalties based on net sales of the licensed products in the designated regions.</p>\n<p>Furthermore, the group will acquire a minority stake in a newly established project company by Clavis Bio’s controlling shareholder (Aditum Bio Fund 3) at zero cost. This collaboration aims to leverage both parties' R&D strengths, enrich the group’s high-value product pipeline, and accelerate global clinical development and commercialization through potential out-licensing, expanding the overseas footprint of its innovative products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1115920738","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115920738","pubTimestamp":1766053961,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) announced that on December 18, 2025, its subsidiary Fosun Pharma Industrial entered into a Collaboration and Option Agreement with Clavis Bio. Under the agreement, during the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0175":"白马股","BK0012":"证金概念","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0096":"民营医院","BK1515":"抗疫概念","02196":"复星医药","BK1191":"制药","BK0188":"融资融券"},"translate_title":"复星医药（600196.SH）子公司与Clavis Bio签署合作及期权协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) announced that on December 18, 2025, its subsidiary Fosun Pharma Industrial entered into a Collaboration and Option Agreement with Clavis Bio. Under the agreement, during the specified collaboration period, Fosun Pharma Industrial and Clavis Bio will jointly select targets (nominated by Clavis Bio) and advance preclinical development for compounds targeting these selected projects.\nClavis Bio retains an exclusive option to develop, manufacture, and commercialize these collaboration projects globally, excluding mainland China, Hong Kong, and Macau. Regardless of whether Clavis Bio exercises this option, the group retains exclusive rights to develop, manufacture, and commercialize the projects in mainland China, Hong Kong, and Macau.\nIf Clavis Bio exercises its option for any project, the group could receive up to $362.5 million in payments (including non-refundable option fees, development and registration milestone payments, and sales milestone payments). Additionally, the group will earn tiered royalties based on net sales of the licensed products in the designated regions.\nFurthermore, the group will acquire a minority stake in a newly established project company by Clavis Bio’s controlling shareholder (Aditum Bio Fund 3) at zero cost. This collaboration aims to leverage both parties' R&D strengths, enrich the group’s high-value product pipeline, and accelerate global clinical development and commercialization through potential out-licensing, expanding the overseas footprint of its innovative products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115920738","isCrawlerRequest":true}